Patents by Inventor Ryan Edward Hill

Ryan Edward Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200339946
    Abstract: The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM, wherein the genomic receiver sites B and D are synthetic constructs designed for recombinase mediated exchange (RMCE).
    Type: Application
    Filed: April 30, 2020
    Publication date: October 29, 2020
    Applicant: GENOVIE AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward HILL, Luke Benjamin PASE
  • Publication number: 20200231974
    Abstract: A combined system comprising two separate components, wherein a first component is a vector carrying variable and constant (V-C) T-cell receptor (TCR) gene segments, and a second component is a vector carrying joining (J) TCR gene segments. The combined system may be modified so that said first component is a modified V-C entry vector encoding a first TCR chain, the system further comprises a fourth and a fifth component, wherein the fourth component comprises a Bidirectional Terminator (BiT) donor vector, and the fifth component comprises a modified V-C entry vector encoding a second TCR chain complimentary to said first TCR chain.
    Type: Application
    Filed: July 17, 2018
    Publication date: July 23, 2020
    Applicant: GENOVIE AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward HILL, Luke Benjamin PASE
  • Publication number: 20200115432
    Abstract: The present invention relates to a two-part device, wherein a first part is an engineered antigen-presenting cell system (eAPCS), and a second part is an engineered TCR-presenting cell system (eTPCS).
    Type: Application
    Filed: November 7, 2017
    Publication date: April 16, 2020
    Applicant: GENOVIE AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward HILL, Luke Benjamin PASE
  • Publication number: 20200095574
    Abstract: The present invention relates to a multicomponent system wherein a first component is an engineered TCR-presenting cell (eTPC), designated component A, wherein component A lacks endogenous surface expression of at least one family of analyte antigen-presenting complexes (aAPX) and/or analyte antigenic molecule (aAM), and a second component is a genetic donor vector, designated component C, for delivery of ORF encoding analyte TCR chains.
    Type: Application
    Filed: November 7, 2017
    Publication date: March 26, 2020
    Applicant: GENOVIE AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward HILL, Luke Benjamin PASE
  • Publication number: 20190359934
    Abstract: The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver GO sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM, wherein the genomic receiver sites B and D are synthetic constructs designed for re-combinase mediated exchange (RMCE).
    Type: Application
    Filed: November 7, 2017
    Publication date: November 28, 2019
    Applicant: GENOVIE AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward HILL, Luke Benjamin PASE
  • Publication number: 20190283017
    Abstract: The present invention relates to a two-part device, wherein a first part is a multicomponent TCR ORF reconstitution and engineering system (TORES), and a second part is a multicomponent engineered TCR-presenting cell system (eTPCS).
    Type: Application
    Filed: November 7, 2017
    Publication date: September 19, 2019
    Applicant: GENOVIE AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward HILL, Luke Benjamin PASE
  • Patent number: 9957531
    Abstract: The invention relates to a genetically engineered bacterium having an enzyme that converts acetyl-CoA to acetoacetyl-CoA, an enzyme that converts acetoacetyl-CoA to 3-hydroxybutyryl-CoA, and an enzyme that converts 3-hydroxybutyryl-CoA to 3-hydroxybutyrate. The bacterium may also have enzymes to produce other downstream products, such as 3-hydroxybutyryaldehyde, and 1,3-butanediol. Typically, the bacterium is capable of producing these products from a gaseous substrate, such as syngas or an industrial waste gas.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: May 1, 2018
    Assignee: LANZATECH NEW ZEALAND LIMITED
    Inventors: Michael Koepke, Rasmus Overgaard Jensen, James Bruce Yarnton Haycock Behrendorff, Ryan Edward Hill, Darmawi Juminaga, Alexander Paul Mueller
  • Publication number: 20180105847
    Abstract: The invention relates to a genetically engineered bacterium having an enzyme that converts acetyl-CoA to acetoacetyl-CoA, an enzyme that converts acetoacetyl-CoA to 3-hydroxybutyryl-CoA, and an enzyme that converts 3-hydroxybutyryl-CoA to 3-hydroxybutyrate. The bacterium may also have enzymes to produce other downstream products, such as 3-hydroxybutyryaldehyde, and 1,3-butanediol. Typically, the bacterium is capable of producing these products from a gaseous substrate, such as syngas or an industrial waste gas.
    Type: Application
    Filed: July 25, 2017
    Publication date: April 19, 2018
    Inventors: Michael Koepke, Rasmus Overgaard Jensen, James Bruce Yarnton Haycock Behrendorff, Ryan Edward Hill, Darmawi Juminaga, Alexander Paul Mueller
  • Patent number: 9738875
    Abstract: The invention relates to a genetically engineered bacterium comprising an energy-generating fermentation pathway and methods related thereto. In particular, the invention provides a bacterium comprising a phosphate butyryltransferase (Ptb) and a butyrate kinase (Buk) (Ptb-Buk) that act on non-native substrates to produce a wide variety of products and intermediates. In certain embodiments, the invention relates to the introduction of Ptb-Buk into a C1-fixing microoorgansim capable of producing products from a gaseous substrate.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 22, 2017
    Assignee: LANZATECH NEW ZEALAND LIMITED
    Inventors: Michael Koepke, Rasmus Overgaard Jensen, James Bruce Yarnton Haycock Behrendorff, Ryan Edward Hill
  • Publication number: 20170101631
    Abstract: The invention relates to a genetically engineered bacterium comprising an energy-generating fermentation pathway and methods related thereto. In particular, the invention provides a bacterium comprising a phosphate butyryltransferase (Ptb) and a butyrate kinase (Buk) (Ptb-Buk) that act on non-native substrates to produce a wide variety of products and intermediates. In certain embodiments, the invention relates to the introduction of Ptb-Buk into a C1-fixing microoorgansim capable of producing products from a gaseous substrate.
    Type: Application
    Filed: October 13, 2016
    Publication date: April 13, 2017
    Inventors: Michael Koepke, Rasmus Overgaard Jensen, James Bruce Yarnton Haycock Behrendorff, Ryan Edward Hill
  • Publication number: 20150152445
    Abstract: The invention provides a recombinant, acetogenic, carboxydotrophic bacterium that lacks secondary alcohol dehydrogenase or comprises an inactivated secondary alcohol dehydrogenase. The inactivated secondary alcohol dehydrogenase may be encoded by a secondary alcohol dehydrogenase gene comprising an inactivating mutation that reduces the ability of the bacterium to convert acetone to isopropanol and to convert methyl ethyl ketone to 2-butanol. Since a bacterium that lacks secondary alcohol dehydrogenase or comprises an inactivated secondary alcohol dehydrogenase accumulates carbonyl-containing compounds, the invention also provides a method of producing carbonyl-containing compounds, such as acetone and methyl ethyl ketone.
    Type: Application
    Filed: December 3, 2014
    Publication date: June 4, 2015
    Inventors: Michael Koepke, Bakir Al-Sinawi, Rasmus Overgaard Jensen, Alexander Paul Mueller, Ryan Edward Hill